Literature DB >> 18344957

Psychological aspects of cytogenetic testing of uveal melanoma: preliminary findings and directions for future research.

S A Cook1, B Damato, E Marshall, P Salmon.   

Abstract

PURPOSE: To determine the proportion of uveal melanoma patients who accept cytogenetic prognostication and to understand the reasons for their decision and the psychological impact of an adverse prognosis.
METHODS: Patients treated by enucleation or local resection for uveal melanoma between 01 January 2003 and 31 December 2006 were identified and the proportion undergoing cytogenetic studies was determined. In-depth interviews of fourteen patients living near our centre were conducted to determine their reasons for accepting cytogenetic testing and their reactions to any results received.
RESULTS: In total 97% of 298 eligible patients with uveal melanoma treated by enucleation or local resection accepted an offer of cytogenetic prognostication. None of the patients interviewed in detail expressed any regret about having this test and there was no evidence of any harm. The main benefit perceived by patients was that they would have greater control and that screening for metastatic disease and early treatment might enhance chances of survival. This was despite counselling that prognostication, screening, and treatment are unlikely to prolong life and that the main purpose of cytogenetic studies is to allow for life-planning.
CONCLUSIONS: Almost all patients with uveal melanoma desire cytogenetic prognostication, although not for the reasons intended by their medical practitioners. Further studies are needed to understand patients' reactions to cytogenetic testing, so that care can be optimised.

Entities:  

Mesh:

Year:  2008        PMID: 18344957     DOI: 10.1038/eye.2008.54

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  19 in total

1.  Dialysis Regret: Prevalence and Correlates.

Authors:  Fahad Saeed; Susan A Ladwig; Ronald M Epstein; Rebeca D Monk; Paul R Duberstein
Journal:  Clin J Am Soc Nephrol       Date:  2020-06-04       Impact factor: 8.237

2.  Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture.

Authors:  B Damato
Journal:  Eye (Lond)       Date:  2012-06-29       Impact factor: 3.775

3.  An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Meghan D Tuscan; J William Harbour
Journal:  J Mol Diagn       Date:  2010-04-22       Impact factor: 5.568

Review 4.  Molecular pathology of uveal melanoma.

Authors:  S E Coupland; S L Lake; M Zeschnigk; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

5.  Reconciling the principle of patient autonomy with the practice of informed consent: decision-making about prognostication in uveal melanoma.

Authors:  Sharon A Cook; Bertil Damato; Ernie Marshall; Peter Salmon
Journal:  Health Expect       Date:  2010-10-28       Impact factor: 3.377

Review 6.  Personalized treatment of uveal melanoma.

Authors:  B Damato; H Heimann
Journal:  Eye (Lond)       Date:  2012-11-23       Impact factor: 3.775

7.  The Patient's Experience of Ocular Melanoma in the US: A Survey of the Ocular Melanoma Foundation.

Authors:  Armin R Afshar; Michael Deiner; Grant Allen; Bertil E Damato
Journal:  Ocul Oncol Pathol       Date:  2018-02-08

8.  Assessment of the effect of iris colour and having children on 5-year risk of death after diagnosis of uveal melanoma: a follow-up study.

Authors:  Andrea Schmidt-Pokrzywniak; Sven Kalbitz; Oliver Kuss; Karl-Heinz Jöckel; Norbert Bornfeld; Andreas Stang
Journal:  BMC Ophthalmol       Date:  2014-04-01       Impact factor: 2.209

9.  The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma.

Authors:  J William Harbour; Royce Chen
Journal:  PLoS Curr       Date:  2013-04-09

10.  Psychosocial impact of prognostic genetic testing in the care of uveal melanoma patients: protocol of a controlled prospective clinical observational study.

Authors:  Yesim Erim; Jennifer Scheel; Anja Breidenstein; Claudia Hd Metz; Dietmar Lohmann; Hans-Christoph Friederich; Sefik Tagay
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.